Analysts' recommendations: Alzinova AB

06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
06/10/25	Alzinova gets fast track designation from US FDA	RE
06/10/25	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT

More recommendations

Managers and Directors: Alzinova AB

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-1.34%	+5.11%	-31.28%	-69.81%	22.12M
LONZA GROUP AG	+0.90%	-2.33%	+0.68%	+14.52%	48B
REVOLUTION MEDICINES, INC.	+1.19%	+8.40%	+410.84%	+561.64%	41.13B
IQVIA HOLDINGS INC.	+3.69%	-4.25%	+28.88%	+8.09%	37.56B
BEONE MEDICINES AG	+1.41%	+0.52%	+7.06%	+75.40%	35.91B
CELLTRION, INC.	+2.42%	+7.27%	+14.90%	+44.79%	29.86B
ASCENDIS PHARMA A/S	+0.08%	-2.72%	-	-	16.12B
MEDPACE HOLDINGS, INC.	+0.94%	-0.76%	+32.96%	+122.78%	16.05B
EUROFINS SCIENTIFIC SE	+1.25%	+1.52%	+4.62%	+18.66%	13.76B
ICON PUBLIC LIMITED COMPANY	+4.16%	-8.32%	-1.58%	-35.07%	12.1B
Average	+1.42%	-1.81%	+51.90%	+82.34%	25.05B
Weighted average by Cap.	+1.64%	-1.29%	+82.28%	+127.76%

See all sector performances

Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-20 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	SEK 1.028	-1.34%	2,087,137
04/08/26	SEK 1.042	-4.93%	4,290,961
03/08/26	SEK 1.096	-5.52%	5,527,250
31/07/26	SEK 1.160	+14.17%	7,413,903
30/07/26	SEK 1.016	+3.89%	2,344,913

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm Other stock markets 00:00:00 06/08/2026 HKT			5-day change	1st Jan Change
1.028 ^SEK	-1.34%		+5.11%	+24.00%

Market Cap	211M 22.26M 19.28M 17.97M 16.53M 31.2M 2.12B 31.55M 82.87M 1.06B 83.59M 81.75M 3.51B	P/E 2026 *	-3.86x	P/E 2027 *	-2.74x
Enterprise Value	195M 20.57M 17.82M 16.61M 15.27M 28.84M 1.96B 29.16M 76.59M 979M 77.25M 75.55M 3.24B	EV / Sales 2026 *	6.22x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-24	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
06-24	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
06-24	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
06-24	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE

07-07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
06-24	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ
06-24	Alzinova signs Letter of Intent with Fujirebio regarding potential commercialization of blood-based Alzheimer’s diagnostic test	AQ
06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ

1 day	-1.34%
1 week	+5.11%
Current month	-11.38%
1 month	+114.17%
3 months	+128.95%
6 months	+32.65%
Current year	+24.00%

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	0.93	1.23
1 month	0.48	1.61
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

	2026 *	2027 *
Net sales	31.35M 3.3M 2.86M 2.67M 2.45M 4.63M 314M 4.68M 12.3M 157M 12.41M 12.14M 521M	-
Net income	-3.2M -337K -292K -272K -250K -473K -32.07M -478K -1.26M -16.05M -1.27M -1.24M -53.15M	-50.35M -5.31M -4.6M -4.28M -3.94M -7.44M -505M -7.52M -19.76M -252M -19.93M -19.49M -836M
Net Debt	-16M -1.69M -1.46M -1.36M -1.25M -2.36M -160M -2.39M -6.28M -80.24M -6.33M -6.19M -266M	-19M -2M -1.73M -1.62M -1.49M -2.81M -190M -2.84M -7.46M -95.28M -7.52M -7.36M -316M